Unipolar Depression – Landscape & Forecast – Disease Landscape & Forecast

The unipolar depression market is crowded and highly genericized. The prominent use of SSRIs and, to a lesser extent, SNRIs as early-line treatments contributes to the challenges branded therapies face when entering this market. Newer-to-market brands (e.g., Lundbeck / Takeda’s Trintellix / Brintellix, Lundbeck / Otsuka Pharmaceutical’s Rexulti / Rxulti) largely compete for use in treatment-resistant depression (TRD) patients, who make up one-third of the major depressive disorder population. The most recent entrant to the depression market, Janssen’s Spravato, offers the fastest onset of therapeutic effect among the approved therapies—fulfilling a key unmet need—but its use for TRD is constrained by multiple factors. Because of remaining unmet needs, physicians will continue to look to emerging therapies—many of which offer novel mechanisms of action—as potential future treatments in this market.

QUESTIONS ANSWERED

  • What factors drive and constrain the use of branded antidepressants and atypical antipsychotics? What branded therapy is expected to experience the greatest commercial success during the forecast period?
  • Given the crowded, highly genericized unipolar depression market, what is the commercial potential of key emerging therapies for unipolar depression?
  • What are the greatest areas of unmet need in the treatment of unipolar depression, and how are therapies in late-phase development expected to address these unmet needs?

CONTENT HIGHLIGHTS

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 24 country-specific interviews with thought-leading psychiatrists; supported by survey data collected for this and other Clarivate research.

Epidemiology: Prevalence of unipolar depression by country, segmented by major depressive disorder, minor depression, and dysthymia; diagnosed / drug-treated prevalence of unipolar depression by country.

Forecast: 10-year, annualized, drug-level sales and patient share of key unipolar depression therapies in 2020-2030, segmented by brands / generics.

Emerging therapies: Phase III/PR: 5 drugs. Coverage of select early-phase products.

Key companies: AbbVie, AstraZeneca, Axsome Therapeutics, Biogen, Gedeon Richter, GlaxoSmithKline, Janssen, Lundbeck, Luye Pharma Group, Otsuka Pharmaceutical, Pfizer, Relmada Therapeutics, Sage Therapeutics, Shionogi, Sumitomo Dainippon, Sunovion, Takeda.

Key drugs: Ansofaxine hydrochloride, aripiprazole, bupropion HCl SR/XR, duloxetine, escitalopram, Latuda (lurasidone), quetiapine IR/XR, Rexulti / Rxulti (brexpiprazole), Spravato (esketamine), Trintellix / Brintellix (vortioxetine), venlafaxine IR/XR, Vraylar / Reagila (cariprazine), AXS-05, REL-1017, seltorexant, zuranolone (SAGE-217).

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Unipolar Depression - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q3 2022
        • July 2022
      • Q2 2022
        • June 2022
        • May 2022
        • May 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
      • Q3 2021
        • August 2021
        • July 2021
    • Key Findings
      • Unipolar Depression - Key Findings - December 2021 UP
        • August 2021
        • July 2021
    • Market Outlook
      • Key Findings
        • Market Share of Unipolar Depression Drug Classes: 2020
        • Market Share of Unipolar Depression Drug Classes: 2030
        • Unipolar Depression SWOT Analysis
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Unipolar Depression?
        • What Factors Are Constraining the Market for Unipolar Depression?
      • Drug-Class-Specific Trends
        • Major-Market Sales of SSRIs in Unipolar Depression, 2020-2030
        • Patient Share of SSRIs in Unipolar Depression in the United States, 2020-2030
        • Patient Share of SSRIs in Unipolar Depression in Europe, 2020-2030
        • Patient Share of SSRIs in Unipolar Depression in Japan, 2020-2030
        • Major-Market Sales of SNRIs in Unipolar Depression, 2020-2030
        • Patient Share of SNRIs in Unipolar Depression in the United States, 2020-2030
        • Patient Share of SNRIs in Unipolar Depression in Europe, 2020-2030
        • Patient Share of SNRIs in Unipolar Depression in Japan, 2020-2030
        • Major-Market Sales and Patient Share of Dopaminergic / Noradrenergic Agents in Unipolar Depression, 2020-2030
        • Major-Market Sales of Atypical Antipsychotics in Unipolar Depression, 2020-2030
        • Patient Share of Atypical Antipsychotics in Unipolar Depression in the United States, 2020-2030
        • Patient Share of Atypical Antipsychotics in Unipolar Depression in Europe, 2020-2030
        • Patient Share of Atypical Antipsychotics in Unipolar Depression in Japan, 2020-2030
        • Major-Market Sales of Mixed Serotonin Modulators in Unipolar Depression, 2020-2030
        • Patient Share of Mixed Serotonin Modulators in Unipolar Depression in the United States, 2020-2030
        • Patient Share of Mixed Serotonin Modulators in Unipolar Depression in Europe, 2020-2030
        • Patient Share of Mixed Serotonin Modulators in Unipolar Depression in Japan, 2020-2030
        • Major-Market Sales of NMDA Receptor Modulators in Unipolar Depression, 2020-2030
        • Patient Share of NMDA Receptor Modulators in Unipolar Depression in the United States, 2020-2030
        • Patient Share of NMDA Receptor Modulators in Unipolar Depression in Europe, 2020-2030
        • Patient Share of NMDA Receptor Modulators in Unipolar Depression in Japan, 2020-2030
        • Sales and Patient Share of Zuranolone (SAGE-217) in Unipolar Depression in the United States, 2020-2030
        • Sales and Patient Share of Seltorexant in Unipolar Depression in the United States, 2020-2030
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Environmental Factors
          • Genetic Factors
            • Select Genes Related to Depression
            • Hypothalamic-Pituitary-Adrenal Axis and Depression
          • Key Pathways and Drug Targets
            • The Monoamine Hypothesis and Antidepressant Drugs
            • SSRI Action at the Serotonergic Synapse
            • Key Pathways and Drug Targets in Unipolar Depression
        • Epidemiology
          • Key Findings
            • Epidemiology Populations
              • Disease Definition
              • Unipolar Depression
              • Major Depressive Disorder
              • Minor Depression
              • Dysthymia
              • Sources for 12-Month Prevalence of Unipolar Depression
              • Number of 12-Month Prevalent Cases of Unipolar Depression in the Major Pharmaceutical Markets by Type, 2020-2030 (thousands)
              • Disease Definition
              • Methods
              • Sources for Comorbid Chronic Pain with Major Depressive Disorder
              • Number of 12-Month Prevalent Cases of Major Depressive Disorder in the Major Pharmaceutical Markets by Chronic Pain Status, 2020-2030 (thousands)
              • Disease Definition
              • Methods
              • Sources for Treatment-Resistant Depression of Major Depressive Disorder
              • Number of 12-Month Prevalent Cases of Major Depressive Disorder in the Major Pharmaceutical Markets by Treatment Stage, 2020-2030 (thousands)
              • Treatment-Resistant Depression: Patient-Flow Diagram
              • Percentage Diagnosed
              • Diagnosed Prevalent Cases of Unipolar Depression: 2020-2030 (thousands)
              • Percentage Drug-Treated
              • Drug-Treated Prevalent Cases of Unipolar Depression: 2020-2030 (thousands)
          • Current Treatment
            • Key Findings
              • Treatment Goals
                • Key Endpoints Used in Clinical Trials for Unipolar Depression
              • Key Current Therapies
                • Overview
                • Mechanism of Action of Key Current Drug Classes Used for Unipolar Depression
                • Current Treatments Used for Unipolar Depression
                • Market Events Impacting the Use of Key Current Therapies in Unipolar Depression
                • Advantages and Disadvantages of Citalopram
                • Expert Insight: Citalopram
                • Advantages and Disadvantages of Escitalopram
                • Expert Insight: Escitalopram
                • Advantages and Disadvantages of Fluoxetine
                • Expert Insight: Fluoxetine
                • Advantages and Disadvantages of Paroxetine
                • Expert Insight: Paroxetine
                • Advantages and Disadvantages of Sertraline
                • Expert Insight: Sertraline
                • Advantages and Disadvantages of Desvenlafaxine
                • Advantages and Disadvantages of Duloxetine
                • Expert Insight: Duloxetine
                • Advantages and Disadvantages of Levomilnacipran
                • Advantages and Disadvantages of Venlafaxine
                • Expert Insight: Venlafaxine
                • Advantages and Disadvantages of Bupropion
                • Expert Insight: Bupropion
                • Advantages and Disadvantages of Aripiprazole
                • Expert Insight: Aripiprazole
                • Advantages and Disadvantages of Brexpiprazole
                • Expert Insight: Brexpiprazole
                • Ongoing Clinical Development of Brexpiprazole
                • Advantages and Disadvantages of Cariprazine
                • Ongoing Clinical Development of Cariprazine
                • Expert Insight: Cariprazine
                • Advantages and Disadvantages of Lurasidone
                • Expert Insight: Lurasidone
                • Advantages and Disadvantages of Quetiapine XR
                • Expert Insight: Quetiapine XR
                • Advantages and Disadvantages of Vilazodone
                • Expert Insight: Vilazodone
                • Advantages and Disadvantages of Vortioxetine
                • Ongoing Clinical Development of Vortioxetine
                • Key Ongoing Clinical Trials of Vortioxetine in the Treatment of Unipolar Depression and Other Psychiatric Disorders
                • Expert Insight: Vortioxetine
                • Agomelatine
                • Advantages and Disadvantages of Agomelatine
                • Expert Insight: Agomelatine
                • Advantages and Disadvantages of Mirtazapine
                • Expert Insight: Mirtazapine
                • Advantages and Disadvantages of Selegiline
                • Expert Insight: Selegiline
                • Advantages and Disadvantages of Esketamine
                • Ongoing Clinical Development of Esketamine
                • Expert Insight: Esketamine
              • Medical Practice
                • Overview
                • Factors Influencing Drug Selection in Unipolar Depression
                • Treatment Decision Tree for Unipolar Depression: United States
                • Treatment Decision Tree for Unipolar Depression: Europe
                • Treatment Decision Tree for Unipolar Depression: Japan
            • Unmet Need Overview
              • Current and Future Attainment of Unmet Needs in Unipolar Depression
              • Expert Insight: Unmet Needs in Unipolar Depression
            • Drug Pipeline
              • Pipeline
              • Regulatory Milestones
              • Indication Comparison
            • Emerging Therapies
              • Key Findings
                • Key Emerging Therapies
                  • Key Therapies in Development for Unipolar Depression
                  • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Unipolar Depression
                  • Zuranolone (SAGE-217) Profile
                  • Key Clinical Trials of Zuranolone (SAGE-217) in the Treatment of Unipolar Depression
                  • Analysis of the Clinical Development Program for Zuranolone (SAGE-217)
                  • Expert Insight: Zuranolone (SAGE-217)
                  • Expectations for Launch and Sales Opportunity of Zuranolone (SAGE-217) in Unipolar Depression
                  • AXS-05 Profile
                  • Analysis of the Clinical Development Program for AXS-05
                  • Expert Insight: AXS-05
                  • Expectations for Launch and Sales Opportunity of AXS-05 in Unipolar Depression
                  • REL-1017 Profile
                  • Key Ongoing Clinical Trials of REL-1017 in the Treatment of Unipolar Depression
                  • Analysis of the Clinical Development Program for REL-1017
                  • Expectations for Launch and Sales Opportunity of REL-1017 in Unipolar Depression
                  • Expert Insight: REL-1017
                  • Ansofaxine Hydrochloride Profile
                  • Expert Insight: Ansofaxine Hydrochloride
                  • Expectations for Launch and Sales Opportunity of Seltorexant in Unipolar Depression
                  • Lumateperone
                  • Lumateperone Profile
                  • Analysis of the Clinical Development Program for Lumateperone
                  • Expectations for Launch and Sales Opportunity of Lumateperone in Unipolar Depression
                  • Expert Insight: Lumateperone
                  • COMP360 psilocybin profile
                  • Analysis of the clinical development program for COMP360 psilocybin
                  • Expert insight: COMP360 psilocybin
                  • Expectations for launch and sales opportunity of COMP360 in unipolar depression
                • Early-Phase Pipeline Analysis
                  • Select Compounds in Early-Phase Development for Unipolar Depression
                • Key Discontinuations and Failures in Unipolar Depression
                • Access and Reimbursement Overview
                  • Region-Specific Reimbursement Practices
                    • Key Market Access Considerations in Unipolar Depression: United States
                    • General Reimbursement Environment: United States
                    • Key Market Access Considerations in Unipolar Depression: EU5
                    • General Reimbursement Environment: EU5
                    • Key Market Access Considerations in Unipolar Depression: Japan
                    • General Reimbursement Environment: Japan
                • Appendix
                  • Unipolar Depression Bibliography

              Login to access report

              launch Related Market Assessment Reports